Dr. Colbourn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000Fax+1 212-794-5847
Education & Training
NYU Grossman Long Island School of MedicineFellowship, Hematology and Medical Oncology, 1986 - 1989- NYU Grossman Long Island School of MedicineResidency, Internal Medicine, 1982 - 1985
Stony Brook University Health Sciences Center School of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1989 - 2026
NY State Medical License 1984 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 12 citationsPralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.Owen A. O'Connor, Jennifer E Amengual, Donald Steven Colbourn, Changchun Deng, Ahmed Sawas
Leukemia & Lymphoma. 2017-07-25 - 32 citationsHigh rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.Lorenzo Falchi, Ahmed Sawas, Changchun Deng, Jennifer E Amengual, Donald Steven Colbourn
Journal of Hematology & Oncology. 2016-11-30 - 1 citationsWill new drugs change the standard of care for patients with mantle cell lymphomaDonald Steven Colbourn, Jennifer E Amengual, Changchun Deng, Ahmed Sawas, Owen A. O'Connor
Expert Review of Anticancer Therapy. 2016-01-01
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaDonald Steven Colbourn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Donald Steven Colbourn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
